<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-133221</identifier>
<setSpec>0212-1611</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Irritable bowel syndrome; gut microbiota and probiotic therapy</dc:title>
<dc:description xml:lang="en">Irritable bowel syndrome (IBS) is characterized by symptoms of abdominal pain and altered bowel habits. This common disorder is managed by varying clinical styles as no dominant therapeutic strategy has emerged. The pathophysiology of IBS remains unknown, but several lines of evidence link this disorder with the gut microbiota. Although controversy exists, gut microbiota is likely contributing to symptoms of IBS, at least in some patients, through an altered fermentation process, an impaired intestinal barrier function, a harmful modulation of enteric sensorimotor function, a promotion of low-grade inflammation without tissue damage, and a harmful modulation of the brain-gut axis. Probiotic therapy has a modest effect on IBS symptomatic relief, but the actual evidence is not strong enough to support a general recommendation of use. The best results are achieved, in children, with Lactobacillus rhamnusus GG, which moderately improves abdominal pain, while in adultsthe benefit appears to be greatest employing Bifidobacterium species (AU)</dc:description>
<dc:creator>Ruiz Ruiz, Mónica</dc:creator>
<dc:creator>Arce González, Marta María</dc:creator>
<dc:creator>Barreiro Alonso, Eva</dc:creator>
<dc:creator>Tojo González, Rafael</dc:creator>
<dc:creator>Roman Llorente, Francisco Javier</dc:creator>
<dc:creator>Pipa Muñiz, María</dc:creator>
<dc:creator>Villegas Diaz, María Francisca</dc:creator>
<dc:creator>Suarez Gonzalez, Adolfo</dc:creator>
<dc:creator>Mancebo Mata, Alejo</dc:creator>
<dc:creator>Moro Villar, María Carmen</dc:creator>
<dc:creator>Mosquera Sierra, Eugenia</dc:creator>
<dc:creator>Rúas Madiedo, Patricia</dc:creator>
<dc:language>es</dc:language>
<dc:description xml:lang="es">El Síndrome de intestino irritable (SII) se define por síntomas de dolor abdominal, y alteración del hábito intestinal. Cuenta con diversos tratamientos disponibles, sin que hasta el momento haya destacado ninguna estrategia terapéutica en especial. La fisiopatología del SII permanece inexplicada, aunque diversas líneas de evidencia sugieren un papel de la microbiota intestinal. A pesar de que existe controversia, es probable que la microbiota contribuya a la generación de síntomas, al menos en algunos pacientes, a través de un proceso de fermentación alterado, de la modificación de la función de barrera intestinal, de la modulación inadecuada de la función sesorio-motora entérica y del eje cerebro-enteral. La probiótico-terapia produce un modesto alivio sintomático en SII, aunque la evidencia actual no es suficiente para la recomendación general de uso. Los mejores resultados se obtienen, en niños, con Lactobacillus rhamnosus GG, que mejora discretamente el dolor abdominal, mientras que en adultos el beneficio parece mayor empleando especies de Bifidobacterium (AU)</dc:description>
<dc:source>Nutr Hosp;31(supl.1): 83-88, feb. 2015. tab</dc:source>
<dc:identifier>ibc-133221</dc:identifier>
<dc:title xml:lang="es">Síndrome de Intestino Irritable; papel de la microbiota y probiótico-terapia</dc:title>
<dc:subject>^d29611</dc:subject>
<dc:subject>^d55394^s22038</dc:subject>
<dc:subject>^d1669</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d38045^s22017</dc:subject>
<dc:subject>^d50446</dc:subject>
<dc:subject>^d33510^s22073</dc:subject>
<dc:type>article</dc:type>
<dc:date>201502</dc:date>
</metadata>
</record>
</ibecs-document>
